In clinical practice, testing for aPL should be limited to patients where APS is suspected—typically in young patients (<50 years) with thrombosis, thrombosis at unusual sites, unexplained recurrent thrombosis, patients with severe pre-eclampsia or HELLP syndrome. Here, FASLG is linked to autoimmune polyendocrinopathy.